NEWEarnings
Immunic Stock Rated Outperform by Wedbush Analysts
Published on 8/17/2026
AI Summary
Summarized by AI from the source belowWedbush has initiated coverage of Immunic, Inc. with an Outperform rating. This rating suggests potential for growth in the company’s stock performance. Immunic is a clinical-stage biopharmaceutical company focused on innovative therapeutics. This move could attract investor interest in Immunic (IMUX), influencing its market performance.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
